New Recommendations for Cabozantinib Tablets in Updated NCCN Clinical Practice Guidelines

September 17, 2018 – Recently, the National Comprehensive Cancer Network® (NCCN®) updated its Clinical Practice Guidelines to include new recommendations for cabozantinib tablets. With the updates, cabozantinib is recommended by the NCCN for the treatment of advanced renal cell carcinoma regardless of patient risk status (favorable-, intermediate-, and poor-risk). Key cabozantinib-related highlights from the updated NCCN Clinical Practice Guidelines for … (leggi tutto)